| Previous close | 20.25 |
| Open | 20.25 |
| Bid | 20.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 20.10 - 20.25 |
| 52-week range | 13.10 - 33.00 |
| Volume | 57,408 |
| Avg. volume | 566,823 |
| Market cap | 22.522M |
| Beta (3Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.00 |
| Earnings date | 4 Dec 2017 - 8 Dec 2017 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 113.00 |
Anyone researching Evgen Pharma plc (LON:EVG) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there Read More...
EVG is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. EVG has created new and stable variants of sulforaphane using its proprietary technology, Sulforadex, enabling it to be used as a therapeutic for the first time. SFX-01 is currently in Phase II trials for both subarachnoid haemorrhage and ER+ metastatic breast cancer, with read-outs expected around the end of 2018.
Evgen (EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. EVG has created new and stable variants of sulforaphane using its proprietary technology, Sulforadex, enabling it to be used as a therapeutic for the first time. SFX-01 is currently in Phase II trials for both subarachnoid haemorrhage (SAH) and ER+ breast cancer, with read-outs expected around the end of 2018.